Viking Therapeutics' Dual GLP-1/GIP Receptor Agonist Shows Promising Results in Phase 1 Clinical Trial.
Viking Therapeutics has initiated a Phase 1 clinical study to evaluate an oral formulation of its dual GLP-1/GIP receptor agonist VK2735. The study will evaluate daily oral doses for 28 days and the results are expected to be available in the second half of 2023. The primary objective of the study is to evaluate the safety and tolerability of VK2735 administered as an oral tablet once daily for 28 days. The secondary objective is to evaluate the pharmacokinetics of orally administered VK2735 in healthy subjects.